A Case of Neuroleptic Malignant Syndrome Presenting as Anxiety
- PMID: 37033557
- PMCID: PMC10080969
- DOI: 10.7759/cureus.35892
A Case of Neuroleptic Malignant Syndrome Presenting as Anxiety
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal complication of dopamine antagonist use. A 34-year-old male presented to the emergency department with a chief complaint of feeling anxious for the past several days. He presented with his family who helped provide history as he had become less communicative over the preceding two days. It was revealed that the patient had a recent psychiatric hospitalization for suspected new-onset psychosis and was discharged six days prior to his presentation. It was reported that the patient was discharged with unknown psychiatric medications but stopped taking them two days prior because he felt they were increasing his anxiety. On physical examination, the patient was found to have upper extremity rigidity and appeared tremulous. A review of records revealed that the patient was discharged from inpatient psychiatric treatment on dual antipsychotic therapy. With this information, the patient met the diagnostic criteria for NMS. He was hospitalized and his symptoms resolved following treatment. Without the knowledge of antipsychotic use, the diagnosis of a serious, life-threatening condition may have been missed. Our case highlights an important but occasionally overlooked aspect of evaluating a patient in the emergency department, namely, outside chart and documentation reviewing.
Keywords: common emergency department complaints; emergency psychiatry; mood and anxiety; neuro-psychiatric; neuroleptic malignant syndrome (nms).
Copyright © 2023, Hanson et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.Ann Pharmacother. 2011 Nov;45(11):e61. doi: 10.1345/aph.1Q325. Epub 2011 Oct 4. Ann Pharmacother. 2011. PMID: 21972252
-
Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.J Med Case Rep. 2022 Oct 6;16(1):366. doi: 10.1186/s13256-022-03591-5. J Med Case Rep. 2022. PMID: 36203196 Free PMC article.
-
[Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].Encephale. 2001 Nov-Dec;27(6):588-99. Encephale. 2001. PMID: 11865567 French.
-
Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management.Asian J Psychiatr. 2017 Oct;29:106-109. doi: 10.1016/j.ajp.2017.05.004. Epub 2017 May 4. Asian J Psychiatr. 2017. PMID: 29061403 Review.
-
Neuroleptic Malignant Syndrome/Malignant Catatonia in Child Psychiatry: Literature Review and a Case Series.J Child Adolesc Psychopharmacol. 2017 May;27(4):359-365. doi: 10.1089/cap.2016.0180. Epub 2017 Feb 23. J Child Adolesc Psychopharmacol. 2017. PMID: 28398818 Review.
References
-
- Emergency department patients with psychiatric complaints return at higher rates than controls. Madsen TE, Bennett A, Groke S, et al. https://resolver.scholarsportal.info/resolve/1936900x/v10i0004/268_edpwp.... West J Emerg Med. 2009;10:268–272. - PMC - PubMed
-
- The hateful physician: the role of affect bias in the care of the psychiatric patient in the ED. Park DB, Berkwitt AK, Tuuri RE, Russell WS. Am J Emerg Med. 2014;32:483–485. - PubMed
-
- Neuroleptic malignant syndrome. Strawn JR, Keck PE Jr, Caroff SN. Am J Psychiatry. 2007;164:870–876. - PubMed
-
- Olanzapine induced neuroleptic malignant syndrome--a case review. Kogoj A, Velikonja I. Hum Psychopharmacol. 2003;18:301–309. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous